Background. Vaccinia virus (VV) membrane proteins are candidates for orthopoxvirus subunit vaccines and potential targets for therapeutic antibodies. Human antibody responses to these proteins after VV vaccination have not been well characterized.
replication, and is thus contraindicated for a significant percentage of the US population [1, [7] [8] [9] .
In response to the increased threat of orthopoxvirus infections, safer vaccines and potent antibody products are being sought. Several in vitro and animal studies have focused on evaluating VV membrane proteins as components of subunit vaccines and as targets of neutralizing monoclonal antibodies [10] [11] [12] [13] . There are 2 important infectious forms of orthopoxviruses, the intracellular mature virus (MV), which is primarily responsible for virus transmission between hosts, and the extracellular enveloped virus (EV), which has been implicated in cell-to-cell virus transmission [12, 14, 15] . B5 and A33 are EVspecific membrane proteins involved with EV formation [16, 17] , whereas the MV membrane-specific A27 and L1 proteins play roles in viral replication and cell attachment [18, 19] . Studies in mice and nonhuman primates have shown that vaccination with these 4 single proteins [10, 20] or with DNA encoding for these proteins elicited variable specific antibody responses and provided partial protection against lethal orthopoxvirus challenge [11, [21] [22] [23] [24] . Protection was enhanced by combining EV and MV proteins and by using DNA vaccine priming followed by protein subunit vaccine boosting. Monoclonal antibodies against these 4 proteins partially protect mice against VV challenge and may be superior to vaccinia immune globulin (VIG) in this function, in particular a humanized anti-B5 monoclonal antibody that has also been shown to neutralize variola virus [12, 13, 25] .
High titers of anti-A33, anti-A27, and anti-B5 antibodies are found in VIG; the latter are responsible for the majority of VIG's EV neutralizing activity [26] [27] [28] . In a recent study describing antibody responses to MV and EV proteins after vaccination with VV strain Lister, anti-B5 antibodies were robustly elicited in nonnaive (previously vaccinated) subjects and accounted for EV neutralization, whereas anti-L1 antibody responses were poor [29] . Here, we report further characterization of specific membrane protein antibody responses in vaccinia-naive and nonnaive human subjects after vaccination with the VV vaccine (Dryvax; Wyeth) used in the United States.
SUBJECTS, MATERIALS, AND METHODS
Subjects and serum specimens. Stored serum specimens were examined from vaccinia-naive and nonnaive adults who participated in 3 National Institute of Allergy and Infectious Diseases-sponsored vaccine clinical trials of diluted and undiluted VV conducted at the Saint Louis University Vaccine and Treatment Evaluation Unit (table 1) [7, 30] . Serum specimens were obtained at multiple time points during the clinical trials and were stored at Ϫ70ЊC until assayed. Each subject provided informed consent for the future use of serum specimens. Saint Louis University and Washington University School of Medicine human experimentation guidelines were followed, and the study was approved by the review boards of both institutions.
Antibody detection. A previously described ELISA used to measure total IgG binding antibodies to whole VV was modified to detect antibodies against the 4 proteins of interest [31] . Briefly, 96-well flat-bottom microtiter plates (MaxiSorp; Nalge Nunc International) were coated with purified, baculovirusexpressed, histidine-tagged recombinant B5, A33, A27 (each at 1.0 mg/mL), and L1 (at 2.0 mg/mL) proteins [32, 33] in carbonate buffer (pH 9.6). The plates were washed in PBS (Invitrogen) containing 0.1% Tween-20 (Sigma) and blocked with PBS containing 5% nonfat milk. Serially diluted serum specimens were added and incubated for 2 h at 37ЊC. The plates were washed, and peroxidase-labeled mouse anti-human IgG Fcg (Accurate Chemical and Scientific Corporation) was added. After a 2-h incubation at 37ЊC, plates were washed and developed with a peroxidase substrate (ABTS; KPL Laboratories). The optical densities were determined using a spectrophotometer at 405/490-nm dual wavelength. End-point titers (EPTs) were calculated as the reciprocal of the highest dilution of serum at which antibody was still detectable, as extrapolated from the best-fit line using the data-reduction software Unitcalc (version 1.1; Biosys Inova). Individual results are reported as the arithmetic mean of duplicate EPT determinations. Paired serum specimens from before vaccination and from days 26-30 after vaccination were analyzed simultaneously. Pooled serum from unvaccinated subjects was used for a negative control. Pooled serum from vaccinated subjects with low whole VV IgG ELISA (EVAC) antibody titers and VIG (VIGIV preparation; Center for Biologics Evaluation and Research, Food and Drug Administration) were used as low-titer and high-titer positive controls, respectively. Assays were repeated per the following quality control criteria: EPT variation 120% between duplicate specimens, nonlinear dilution curves, negative control with optical densities above the threshold value (0.2 for the A27 assay and 0.15 for the others), or VIG titers varying by 12 SDs from the mean titer for all assays performed.
Confirmation of low anti-L1 antibody responses. Purified L1 protein was added in increasing concentrations to VIG to adsorb anti-L1 antibodies. ELISAs (as described above) confirmed an appropriate dose-response reduction of anti-L1 antibodies after preincubation with specific antigen (data not shown).
Data management and statistical analysis. Subject characteristics, prior vaccination status, major cutaneous reaction status, and adverse effects data had been collected during each of the original clinical trials. Intracellular MV plaque reduction neutralizing (PRNT) antibody and EVAC antibody assays were performed during the original clinical trials [7, 30, 34] , and the results were compared with the membrane protein-specific ELISA antibody responses as described above. Antibody responses were evaluated by the presence of postvaccination antibodies, the titers of pre-and postvaccination antibodies, and the fold increase in antibody titers after vaccination. For data analysis purposes, specimens with undetectable antibodies were assigned a reciprocal EPT of 50% of the lower limit of detection, which was 100 for all ELISAs and 20 for PRNT antibodies. Fold increases were calculated as the postvaccination titer divided by the prevaccination titer or as the postvaccination titer divided by the lower limit of detection when prevaccination antibodies were not detected. Summary titers were reported as geometric mean titers (GMTs). Categorical variables were compared by x 2 or Fisher's exact test (for independent variables) or by McNemar's test with small-sample correction (for nonindependent variables). For each antibody, titers were compared between before and after vaccination by paired t tests and between vaccinia-naive and nonnaive recipients by independentsamples t tests. Nonnormally distributed continuous variables were log transformed before comparisons. Nonparametric Mann-Whitney U tests were also used to compare vaccinianaive and nonnaive subjects. Because the statistical conclusions were similar, only results from parametric analyses are reported here. For evaluation of specific antibody detection as a test to predict immunity, sensitivity, specificity, and positive and negative predictive values were calculated per standard definitions [35] . SPSS (version 12; SPSS Institute) was used for all analyses. A 2-tailed significance level of .05 was used.
RESULTS
Study subjects. Serum specimens from 80 vaccine trial participants were analyzed. One nonnaive subject yielded uninterpretable results to multiple tested antibodies because of nonlinear dilution curves, leaving evaluable serum from 79 subjects. Serum specimens from 29 vaccinia-naive and 29 nonnaive subjects who received undiluted vaccine and from 21 nonnaive subjects who received vaccine diluted 1:10 were analyzed. Three A27 specimens (all from nonnaive subjects, 1 of whom received diluted vaccine) and 1 L1 specimen (from a nonnaive subject who received diluted vaccine) did not meet quality control criteria and were excluded. Vaccinia-naive subjects were younger than the nonnaive subjects as a result of the original trial inclusion criteria but were otherwise similar (table 1) . Dilutedvaccine recipients were slightly younger than undiluted-vaccine recipients.
Antibody detection in VIG. VIG used as an ELISA positive control demonstrated consistently detectable antibodies for each of the membrane protein-specific antibodies studied. GMTs were 7631 (95% confidence interval [CI], 6679-8722), 2347 (95% CI, 2052-2685), 2295 (95% CI, 1987-2652), and 507 (95% CI, 421-611) for anti-B5, anti-A33, anti-A27, and anti-L1, respectively.
Antibody responses in vaccinia-naive subjects. No membrane protein antibodies were detected in prevaccination serum from 24 (83%) of 29 vaccinia-naive subjects. One subject (3%) had detectable antibodies to all 4 proteins (EPTs of 381, 190, 361, and 186 for anti-B5, anti-A33, anti-A27, and anti-L1, respectively), possibly representing unrecognized prior vaccination, whereas 4 other subjects (14%) each had detectable antibodies to only 1 of the 4 proteins (EPTs of 506, 174, 149, and 114 for anti-B5, anti-A33, anti-A27, and anti-L1, respectively). After vaccination, all subjects had detectable antibodies to at least 1 of the membrane proteins. Fifteen subjects (52%) had antibodies against all 4 of the tested proteins, and 2 subjects (7%) had antibodies against a single membrane protein (A33) only. Antibody responses to A33 were universal, and all subjects with either anti-B5 or anti-L1 antibodies also had both anti-A33 and anti-A27 antibodies. Compared with PRNT antibodies (97% detected), anti-B5 (69%;
) and anti-L1 (62%; P p .04 ) antibodies were less frequently elicited ( figure 1A) . P p .01 Postvaccination antibody titers are illustrated in figure 1B. Titers were not associated with age, sex, or race for any of the membrane protein antibodies. Preexisting and elicited antibodies in nonnaive subjects. Preexisting anti-EV (anti-B5 or anti-A33) antibodies were detected in 40 nonnaive subjects (80%), and anti-MV (anti-A27 or anti-L1) antibodies were detected in 20 (40%) ( figure 2A ). Anti-L1 antibodies were detected in only 5 subjects (10%). Anti-B5 titers were negatively correlated with age ( ); P p .02 otherwise, none of the other specific antibody titers were associated with age, sex, or race. There was indirect evidence suggesting that anti-B5 antibodies may persist with little decay, because preexisting anti-B5 titers in nonnaive subjects (GMT, 154) were similar to postvaccination anti-B5 titers in vaccinianaive subjects (GMT, 183) ( ). P p .46 For the 29 nonnaive subjects receiving undiluted vaccine, all 4 membrane protein antibodies were detected more frequently after vaccination compared with before vaccination (figure 2A). After vaccination, 9 subjects (31%) had detectable antibodies to all 4 of the tested proteins. One had anti-B5 antibodies only (EPT, 173), and 1 had no membrane protein antibodies; in both of these subjects, vaccination elicited major cutaneous reactions and low-titer EVAC (EPTs, 384 and 311) and PRNT antibodies (titers, 113 and 230). Overall response to B5 was excellent-with 28 subjects (97%) having detectable antibodies at very high titers (GMT, 1010) and with the highest postvaccination increase (9.6-fold) of all the membrane protein-specific antibodies-whereas anti-L1 antibody responses were poor by all measures. Only 9 subjects (31%) developed detectable anti-L1 antibodies, which were of low titer (GMT, 75), and there was minimal boosting (1.2-fold titer increase and none with a 4-fold titer increase). In comparison, EVAC and PRNT antibodies were present in all subjects, were of high titer (GMT for EVAC, 1813; GMT for PRNT, 4131), and more frequently exhibited a 4-fold or greater postvaccination increase than any of the membrane protein antibodies (figure 2B). Postvaccination titers were significantly higher than prevaccination titers for all tested antibodies except anti-L1 ( figure 2C-2H) .
Responses in vaccinia-naive versus nonnaive subjects. Antibody responses to undiluted VV vaccination differed by prior vaccination status (figure 3). Postvaccination anti-B5 antibodies were more frequently detected (97% vs. 69% for nonnaive vs. naive;
) and of higher titer (GMT, 1010 vs. 183; P ! .01 ) in nonnaive subjects ( figure 3A) . Likewise, postvacci-P ! .01 nation EVAC antibody titers were 110-fold higher in nonnaive subjects (GMT, 4131 vs. 314 for nonnaive vs. naive; ) P ! .01 ( figure 3E) .
Effect of vaccine dilution. Among the 21 nonnaive subjects who received vaccine diluted 1:10, the proportion of postvaccination detectable antibodies, titers, and fold increases for all specific antibodies were not significantly different from those among the 29 nonnaive subjects who received undiluted vaccine (data not shown).
Correlation between membrane protein-specific antibodies and PRNT antibodies. Aggregate specific antibody EPTs from all 79 subjects were examined for correlation with PRNT antibody titers (figure 4). Anti-B5 ( ), anti-A33 ( ), r p 0.74 r p 0.73 and anti-A27 ( ) antibodies correlated moderately well r p 0.73 with PRNT antibodies.
Immunity predicted by specific antibodies. All vaccinianaive subjects developed a major reaction after vaccination, whereas 3 (6%) nonnaive subjects did not develop a major reaction. Two of these received diluted vaccine, and 1 received undiluted vaccine. Neither the presence nor titer of any preexisting antibodies was associated with the development of a major reaction. Among all nonnaive subjects, postvaccination antibody titer fold increases, but not GMTs, were significantly higher in subjects with a major reaction than in those without for all antibodies except anti-A27 and anti-L1 (table 2) . Among nonnaive subjects, no single antibody response was an accurate predictor of immunity, as indicated by development of a major reaction. The presence of anti-L1 antibodies after vaccination had a specificity and positive predictive value of 100% for predicting a major reaction, as all 15 subjects with detectable anti-L1 antibodies exhibited one; however, the sensitivity and negative predictive values were extremely poor (33% and 9%, respectively). Conversely, the postvaccination presence of all other antibodies exhibited 91%-100% sensitivities and 193% positive predictive values for predicting a major reaction, but all had specificities of 0% except for anti-A27 (33% specificity).
DISCUSSION
Because of the potential risk of intentional or accidental variola virus release and the persistence of monkeypox in Africa, safer orthopoxvirus vaccines and more-efficacious immunotherapeutic agents are being sought. Subunit vaccines derived from orthopoxvirus proteins are likely to be less reactogenic than currently available VV vaccines; however, the optimum composition of viral proteins has not been determined. Our report provides further characterization of VV membrane protein antibody responses in vaccinia-naive and nonnaive human subjects and confirms several important findings recently reported by Pütz et al. [29] . Neutralizing antibodies against both EV and MV are thought to be necessary for full protection against orthopoxvirus infections [10, 12, 22, 24, 36, 37] . Anti-B5 antibodies neutralize EV and inhibit its spread from infected cells, and they may be the most important component of anti-EV responses and protective immunity [26, 32, 38] . This is highlighted by Chen et al. [13] , who reported that an anti-B5 neutralizing monoclonal antibody alone may be sufficient to fully protect mice from lethal VV challenge. Similar to previous reports [29] , our data clearly show that anti-B5 responses are robust and are relatively stronger than anti-MV responses in nonnaive individuals. The long-term persistence and vigorous boosting of anti-B5 antibodies that we observed may account for the longer duration of immunity thought to be imparted by multiple vaccinations [6] . These findings suggest that anti-B5-specific memory responses could be attributable to long-lasting anti-B5-specific memory B cells, as has been reported similarly for antibodies to H3, an MV protein [39] , and provide further evidence that B5 should be a critical component of subunit vaccines.
Antibody responses to other EV proteins, such as A33, may also be important for complete protection. The comet assay is a marker for release of EV from infected cells and is efficiently inhibited by anti-A33 antibodies, which do not neutralize EV in a PRNT assay [12, 26] . Immunization with A33 provides partial protection in mice against challenge with VV or the closely related ectromelia virus [20, 40] , suggesting that clinical protection may not be the result of virus neutralization alone. Furthermore, in a recent primate monkeypox challenge study, binding antibodies to the monkeypox orthologue of A33 were inversely correlated with the number of lesions [24] . In the present study, anti-A33 antibodies were robustly elicited by VV vaccine in vaccinia-naive subjects and were moderately boosted in nonnaive subjects.
The MV-specific protein L1 seems to be poorly immuno- genic, given that we observed anti-L1 antibodies to be infrequently present and of low titer, consistent with Pütz et al.'s recent findings [29] . Although L1 is known to be immunogenic in animals, anti-L1 antibody responses appear to be more robust after vaccination with L1 by itself than in combination with other proteins [11] . Although anti-L1 antibodies have the ability to neutralize MV, their role remains unclear in the overall humoral response to orthopoxviruses in humans. A possible explanation for poor anti-L1 antibody responses after VV vaccination is the limited quantity of L1 on the MV membrane of VV, compared with A27, which is the most abundant MV protein [41] . Although our data call into question the importance of L1 as an immunogen for eliciting humoral immunity after VV vaccination, they do not preclude the possibility that this protein could be important for immunity after subunit vaccination.
We noted significant differences in the patterns of membrane protein antibody responses to VV vaccine depending on prior vaccination status. Anti-A33 and anti-A27 antibody responses were robust in naive subjects. Conversely, nonnaive subjects exhibited a vigorous boosting of anti-B5 antibodies, averaging a nearly 10-fold increase in titers. These differences have implications for the optimal composition of a subunit vaccine. For example, B5 would likely be an important component when used for revaccination of nonnaive individuals. In addition, the preexisting PRNT and anti-EV antibodies in nonnaive subjects, most of whom were probably vaccinated 130 years ago, adds to the growing body of evidence that partial humoral immunity lasts well beyond the 5-10 years thought to be the duration of reliable clinical protection imparted by vaccination [4, 6, 36, 42] .
Vaccination with VV vaccine diluted 1:10 was previously demonstrated to elicit major reaction rates similar to those for undiluted vaccine but was associated with higher PRNT antibody titers, reduced local inflammatory responses, and increased satellite lesions in vaccinia-naive subjects [7, 43] . However, we observed no differences in membrane protein-specific or PRNT antibody responses in the subset of nonnaive subjects who received diluted vaccine, implying that the vaccine antigen dose-dependent antibody response observed in vaccinia-naive subjects may be attenuated by preexisting immunity.
Surrogate markers of immunity are important for estimating the efficacy of orthopoxvirus vaccines, for which clinical efficacy cannot be measured by disease acquisition after exposure. Although the major reaction elicited by replicating VV vaccine is an excellent surrogate for clinical immunity, other markers will be necessary for evaluating subunit and other nonreplicating or minimally replicating vaccines, such as modified vaccinia Ankara (MVA) [44] . We found that antibody responses directed against specific membrane proteins were quite variable within each of the groups studied. This phenomenon was also noted previously in animals vaccinated with VV or with subunit vaccines [23, 27] . In humans, it is unclear whether this represents host variability, variation in dose of vaccine delivered, or variability of viral clones in calf lymph-derived replicating VV vaccine [45] . This observed variability suggests that a single characteristic pattern of membrane protein-specific antibody responses to VV vaccine may not exist. Because the equivalent MVA membrane protein genes share 98%-100% homology with other vaccinia strains, it is anticipated that specific antibody responses to MVA would show similar variability [46] .
Furthermore, there were too few subjects without a major reaction in the present study to assess the usefulness of specific antibody responses as predictors of immunity. For example, anti-A33 antibody detection was highly sensitive for predicting immunity in vaccinia-naive subjects, but its specificity could not be determined because all of the vaccinia-naive subjects developed a major reaction. All subjects with postvaccination anti-L1 antibodies developed a major reaction, making this a highly specific test, but this finding is of limited value given the low percentage of subjects responding to L1. Thus, there is insufficient evidence that any of the membrane proteinspecific antibodies are better for predicting clinical immunity than anti-MV PRNT antibodies after vaccination with VV [6] . However, anti-MV PRNT antibodies may not be as good a predictor of protection after vaccination with a subunit vaccine. This was demonstrated by Hooper et al. [11] , as mice vaccinated with A27 alone developed high-titer PRNT antibodies but were not reliably protected against viral challenge, probably because anti-EV antibody responses were not elicited.
Our study has several recognizable limitations. First, although overall immunity to orthopoxviruses is thought to be mostly dependent on humoral responses, which may be sufficient to provide full protection in some instances [5, 13, 36] , cell-mediated and innate immune responses are likely important but were not addressed in the present study [47] [48] [49] . Second, we examined polyclonal total IgG binding antibody re-sponses only and did not address functionality. Third, data on the number of previous vaccinations or time since vaccination in nonnaive subjects were not available; thus, it was not possible to determine the relative importance of these variables with respect to antibody titers. Finally, a more in-depth evaluation of nonresponders is needed to better assess the performance characteristics of specific membrane protein ELISAs for predicting immunity.
In conclusion, we have provided further characterization of normal human antibody responses to specific VV membrane proteins after vaccination with VV. The EV and MV membrane proteins studied were variably immunogenic, as vaccinia-naive subjects responded best to A33 and A27 and nonnaive subjects exhibited vigorous boosting of B5. Anti-L1 antibody responses were poor in both groups. There is good evidence that B5, A33, and A27 could be important components of subunit vaccines and targets for monoclonal antibody products.
